851 related articles for article (PubMed ID: 10718823)
1. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
Gerding MN; van der Meer JW; Broenink M; Bakker O; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 2000 Mar; 52(3):267-71. PubMed ID: 10718823
[TBL] [Abstract][Full Text] [Related]
2. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods.
Morris JC; Hay ID; Nelson RE; Jiang NS
Mayo Clin Proc; 1988 Jul; 63(7):707-17. PubMed ID: 2898572
[TBL] [Abstract][Full Text] [Related]
4. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
5. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
6. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
7. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy.
Khoo DH; Ho SC; Seah LL; Fong KS; Tai ES; Chee SP; Eng PH; Aw SE; Fok AC
Thyroid; 1999 Dec; 9(12):1175-80. PubMed ID: 10646655
[TBL] [Abstract][Full Text] [Related]
8. Further evaluation of an immunoprecipitation assay for TSH-receptor autoantibodies in Graves' disease.
De Bruin TW; Braverman LE; Brown RS
Metabolism; 1986 Dec; 35(12):1101-5. PubMed ID: 2878349
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
Aizawa Y; Yoshida K; Kaise N; Kaise K; Fukazawa H; Kiso Y; Mori K; Sayama N; Kikuchi K; Abe K
Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
[TBL] [Abstract][Full Text] [Related]
10. Endocrine ophthalmopathy: a re-evaluation of the association with thyroid autoantibodies.
McLachlan SM; Bahn R; Rapoport B
Autoimmunity; 1992; 14(2):143-8. PubMed ID: 1363894
[TBL] [Abstract][Full Text] [Related]
11. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.
Kasagi K; Hatabu H; Tokuda Y; Iida Y; Endo K; Konishi J
Clin Endocrinol (Oxf); 1988 Oct; 29(4):357-66. PubMed ID: 2908031
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.
Kim WB; Chung HK; Park YJ; Park DJ; Lee HK; Cho BY
Korean J Intern Med; 2001 Sep; 16(3):187-200. PubMed ID: 11769578
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
Maugendre D; Massart C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.
Sarić Matutinović M; Diana T; Nedeljković Beleslin B; Ćirić J; Žarković M; Kahaly GJ; Ignjatović S
J Endocrinol Invest; 2022 Jan; 45(1):189-197. PubMed ID: 34324163
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of anti-TSH antibody in TSH binding inhibitory immunoglobulin-positive sera of patients with Graves' disease.
Ochi Y; Hamazu M; Kajita Y; Nagata A
Clin Endocrinol (Oxf); 2002 Mar; 56(3):405-12. PubMed ID: 11940054
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
[TBL] [Abstract][Full Text] [Related]
17. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease.
Goh SY; Ho SC; Seah LL; Fong KS; Khoo DH
Clin Endocrinol (Oxf); 2004 May; 60(5):600-7. PubMed ID: 15104563
[TBL] [Abstract][Full Text] [Related]
18. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N
Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425
[TBL] [Abstract][Full Text] [Related]
19. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
